BioLife Solutions, Inc. · NASDAQ:BLFS
BioLife Solutions — OneMed Forum (January 2015)
46 slides from BioLife Solutions's conference presentation, January 2015
Slide 1: Investor Presentation January 2015
NASDAQ:BLFS Investor InvestorPresentation Presentation January January2015 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the anticipated business and operations of our new joint venture, the potential utility of and market for its planned products and services, its expected finances, potent
Slide 3: Best-in-class life sciences tools provider
NASDAQ: BLFS Best-in-class life IP embedded in 175 sciences tools regenerative medicine provider clinical trials 25% annual core $10M cash, no debt products revenue at 12/31/14 growth 3
Slide 4: Biopreservation
BIOPRESERVATION BIOLOGISTICS 4
Slide 5: Biopreservation
Biopreservation The scientific methods and tools used to effectively preserve biologic materials outside the body by ensuring … survival recovery functional performance … when used in clinical infusion, injection, or transplantation in patients 5
Slide 6: Ex-Vivo Survival of Biologics
Ex-Vivo Survival of Biologics 6
Slide 7: Biopreservation in Regenerative Medicine
BIOPRESERVATION IN REGENERATIVE MEDICINE Source Preservation Temperature Material Media Controlled Container Patient Cell Factory Preservation Media Temperature Manufactured Controlled Products Container BIOLOGISTICS 7
Slide 8: Complementary Biopreservation Tools Platforms
Complementary Biopreservation Tools Platforms Each is Critical to our Customers’ Clinical and Commercial Success Biopreservation Smart Shipping Media for Cells Containers 8
Slide 9: Biopreservation Media Products
BIOPRESERVATION MEDIA PRODUCTS 9
Slide 10: Clinical Grade Biopreservation Storage Media
Clinical Grade Biopreservation Storage Media Engineered to improve yield and extend shelf-life of biologics Better cell yield More precious cells saved, reduced variable costs Longer shelf-life of clinical cells Lower customer MFG CAPEX requirements 10
Slide 11: HypoThermosol FRS
HYPOTHERMIC STORAGE AND SHIPPING MEDIA HypoThermosol FRS® Decreases free radical accumulation in cold storage process Balances intracellular state at low temperatures Improved yield and extended stability of cells and tissues 11
Slide 12: CryoStor
CRYOPRESERVATION / FREEZE MEDIA CryoStor® Improved yield of cells and tissues Mitigates molecular cell stress during freezing and thawing 12
Slide 13: Better Cell Yield
BETTER CELL YIELD Increased cell survival; reduced costs Condition of cells after 5 days of cold storage Traditional Home Brew Media BioLife Storage Media 13
Slide 14: Enabling Manufacturing Cost Reductions for Our Customers
Enabling Manufacturing Cost Reductions for Our Customers Increased yield leads to … … decreased cost Source Material Manufactured Cell Products LESS LESS Required Required Yield Yield Cost Cost 14
Slide 15: Limited Shelf-Life
Increased CAPEX requirements for LIMITED SHELF-LIFE manufacturers of cellular therapeutics Distribution range limited by short shelf-life - multiple production facilities required 15
Slide 16: Longer Shelf Life, Reduced CAPEX Requirements
LONGER SHELF LIFE Reduced CAPEX Requirements BioLife Solutions Preservation Media Performance Extends Shelf Life to Support Worldwide Distribution of Cellular Therapeutics 16
Slide 17: Demand for Biopreservation Media
DEMAND FOR BIOPRESERVATION MEDIA (MILLIONS) $900 $820.0 $700 Major growth expected from Regenerative $500 Medicine segment $345.0 $300 $100 2004 2019 Source: Biopreservation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 (Transparency Market Research, April,
Slide 18: Biologistics
BIOPRESERVATION BIOLOGISTICS 18
Slide 19: Biologistics
Biologistics The processes, tools, and data used to manage and monitor the movement of biologic materials across time and space to ensure… secure, on-time arrive at the destination maintenance within validated temperature patient dosing within the validated stability profile 19
Slide 20: Biologistics Drivers
Biologistics Drivers • All vaccines and 70% of biologics are temperature sensitive • Cold chain yield losses due to improper storage are significant – up to 3% annually in pharma • In the developing regenerative medicine market, clinical therapies include simple to complex, sensitive cells and tissu
Slide 21: Current Paradigm
Current Paradigm • Billions spent annually on cold chain logistics of drugs, vaccines, cells, tissues, and organs (iMARC Group 12/2013) • Limited use of real-time temperature monitoring and reporting during shipment (“validate then assume” approach) • Significant opportunities exist to reduce cost a
Slide 22: Demand for Biopreservation Equipment: Cold Chain Shippers and Instruments
DEMAND FOR BIOPRESERVATION EQUIPMENT COLD CHAIN SHIPPERS AND INSTRUMENTS (BILLIONS) 2013 Worldwide Cold Chain Spend: $7.5 Billion Transportation Specialized Packaging $2,600,000,000 $4,900,000,000 Source: IMS Health, Evaluate Pharma 22
Slide 23: Demand for Biopreservation Equipment: Cold Chain Shippers and Instruments
DEMAND FOR BIOPRESERVATION EQUIPMENT COLD CHAIN SHIPPERS AND INSTRUMENTS (BILLIONS) $6 $5.1 $5 $4 $3.2 $3 $2 $1 $0 2013 2018 Source: iMarc Group, December 2013 23
Slide 24: Customer Risks
Customer Risks • Clinical: • Administering a thermally sensitive biologic dose that was exposed to unknown temperature excursions or opened during transit • Economic: • Cost of scrapping biologic source material or manufactured cell product due to: • Identified temperature excursion • Unable to loca
Slide 25: Competition – Foam Coolers
COMPETITION – FOAM COOLERS • Expanded polystyrene foam • Extruded polystyrene foam • Minimal performance • Technology essentially unchanged for over 25 years • Single use 25
Slide 26: Competition – Vacuum Panel Shipper
COMPETITION – VACUUM PANEL SHIPPER • Very large footprint • Expensive to ship • Heavy • Complicated assembly • Refrigerants must be preconditioned to multiple temperature ranges before use 26
Slide 27: Biologistics Products & Services
BIOLOGISTICS PRODUCTS & SERVICES 27
Slide 28: EVO Smart Container
EVO™ - SMART CONTAINER • Reusable • Simple packout process • Payload cavity sized for typical regenerative medicine final product packaging 28
Slide 29: Biologistex CCM: Breakthrough Disruptive Technology
Biologistex CCMSM: Breakthrough Disruptive Technology • Reusable, super insulating shipping container • Smart box – integrated cell phone and payload monitoring electronics • Cloud-hosted biologistics management app • Innovation driving best quality practices in logistics of regenerative medicines •
Slide 30: Web App – SaaS Business Model
Web App – SaaS Business Model 30
Slide 31: SaaS Business Model
SaaS Business Model Potential to Build a Base of Thousands of Shippers Deployed Throughout the World – Each Generating Subscription Revenue for Rental and Data Access 31
Slide 32: Contract Manufacturing Services
CONTRACT MANUFACTURING SERVICES • Utilizing excess production capacity • Niche provider of aseptic media formulation, fill, and finish services • New multiyear agreement with Somahlution, LLC 32
Slide 33: Our Markets
OUR MARKETS II BioLire SOLUTIONS’ BIOPRESERVATION TOOLS FOR CELLS, TISSUES, AND ORGANS
Slide 34: We Serve Traditional and Emerging Markets
WE SERVE TRADITIONAL AND EMERGING MARKETS Traditional Markets Emerging Market • Stable, growing (in $M) • Explosive growth (in $B) • Well-established relationships • BioLife products embedded in 175 trials • Reliable income streams Drug Regenerative Biobanking Discovery Medicine BIOLOGISTICS 34
Slide 35: Biobanking
BIOBANKING • Umbilical cord blood banks • Adult stem cell banks • Tissue banks • Biorepositories • Hair transplant physicians 35
Slide 36: Drug Discovery
DRUG DISCOVERY • Pharmaceutical companies • Cell suppliers • Toxicity testing labs 36
Slide 37: Regenerative Medicine
REGENERATIVE MEDICINE • Commercial cell therapy and tissue engineering companies • Hospital-based stem cell transplant centers • University-based clinical research labs 37
Slide 38: Regenerative Medicine Customer Base
REGENERATIVE MEDICINE CUSTOMER BASE Stroke ALD & MS ALS UTD* AMD AMI CHF & DCM Liver Disorders GVHD Spinal Disorders HIV Lymphoma Melanoma AML Autoimmune Incontinence UTD* Cancer Wound healing Joint Repair CLI Cancer * UNABLE TO DISCLOSE 38
Slide 39: Products Used in 175 Clinical Trials
Products Used in 175 Clinical Trials Indication Pre-Clinical Phase I Phase II Phase III Solid Tumors 4 17 36 5 Hematologic Malignancies 8 8 11 2 Heart Disease 1 2 8 2 Stroke 0 0 4 0 Joint Disease 4 1 1 2 Vision Loss 1 1 0 0 Immune Disorders 8 9 9 2 All Others 7 9 8 8 Totals 33 47 77 21 39
Slide 40: BioLife Products Embedded in Cellular Immunotherapy
BioLife Products Embedded in Cellular Immunotherapy DISCLOSED CUSTOMERS CONFIDENTIAL Nearly all other high- profile, development stage immunotherapy companies; unable to disclose at this time 40
Slide 41: Global Regenerative Medicine Market Revenue
GLOBAL REGENERATIVE MEDICINE MARKET REVENUE (USD BILLIONS) 25 $23.3 20 15 10 5 $3.6 0 2012 2024 Source: visiongain – December 2013 41
Slide 42: Investment Opportunity
INVESTMENT OPPORTUNITY 42
Slide 43: Well Positioned for Future Growth
Well Positioned for Future Growth • Over 500 existing customers • Growing adoption in expanding biobanking and drug discovery markets • Embedded in rapidly emerging regenerative medicine market with products incorporated in over 175 clinical trials; 21 in Phase III • New biologistex SaaS business po
Slide 44: Investment Fundamentals
INVESTMENT FUNDAMENTALS December 31, 2014 Cash and Investments $10M Total Debt $0.00 Total Stockholder Equity $12.7M Shares Outstanding 12M 3/25/14 – issued 3.6M shares at $4.30 Options 1.4M most in the money Warrants 7.4M most at $4.75 – debt conversion/equity raise Average Volume ~25,000 shares Ma
Slide 45: Continued adoption of core products
Continued adoption of core products – creates tremendous upside as customers gain approvals to market regenerative medicine products and therapies biologistex CCMsm cold chain management service – complementary to core business Niche, profitable CMO business 45
Slide 46: BioLife Solutions, Inc.
NASDAQ:BLFS BioLife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 For additional questions or comments, please contact: Michael Rice | President and CEO mrice@BioLifeSolutions.com | (425) 686-6003 Daphne Taylor | CFO, VP - Finance & Administration dtaylor@BioLifeSolutions.com